Actavalon

Actavalon is a Seattle-based biotechnology company focused on developing first-in-class small molecule therapeutics that restore the function of the p53 tumor suppressor protein. Known as the "guardian of the genome," p53 is the most frequently mutated gene in human cancer, yet it has historically been considered an undruggable target. The company's proprietary platform is based on decades of research into protein folding and stability, specifically designed to identify compounds that can refold and reactivate mutant p53. By restoring the natural ability of p53 to induce cell cycle arrest and apoptosis in malignant cells, Actavalon aims to provide transformative treatments for a wide range of hard-to-treat solid tumors. The company was founded by world-renowned protein scientist Sir Alan Fersht and is currently advancing its lead programs through the preclinical stage.